Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 3, Issue 1, 2017, Pages 11-17

  Vries, Minka J A ^a   Bouman, Heleen J ^b   Olie, Renske H ^b   Veenstra, Leo F ^b   Zwaveling, Suzanne ^a   Verhezen, Paul W M ^b   Ten Cate Hoek, Arina J ^a,b   Ten Cate, Hugo ^a,b   Henskens, Yvonne M C ^a,b   Van Der Meijden, Paola E J ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Concordance; Coronary artery disease; Influencing factors; P2Y12 inhibitors; Platelet reactivity test

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; HEMOGLOBIN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CORONARY ARTERY DISEASE; EXPLORATORY RESEARCH; FEMALE; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; VULNERABLE POPULATION; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECT; FOLLOW UP; PLATELET COUNT; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

AGED; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TICLOPIDINE; TREATMENT OUTCOME; VULNERABLE POPULATIONS;

EID: 85039772762     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvw026     Document Type: Article

References (33)

1. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data. Lancet 2009;374:1967-1974.
2. Jensen LO, Maeng M, Thayssen P, Kaltoft A, Tilsted HH, Bottcher M, Lassen JF, Hansen KN, Krusell LR, Rasmussen K, Pedersen KE, Pedersen L, Paaske Johnsen S, Sorensen HT, Thuesen L. Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with STsegment elevation myocardial infarction. Circ Cardiovasc Interv 2008;1:176-184.
3. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-2273.
4. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36:1762-1771.
5. Vries MJ, van der Meijden PE, Henskens YM, Ten Cate-Hoek AJ, Ten Cate H. Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review. Thromb Haemost 2015;115:7-24.
6. Sabouret P, Rushton-Smith SK, Kerneis M, Silvain J, Collet JP, Montalescot G. Dual antiplatelet therapy: Optimal timing, management, and duration. Eur Heart J Cardiovasc Pharmacother 2015;1:198-204.
7. Aradi D, Komocsi A, Price MJ, Cuisset T, Ari H, Hazarbasanov D, Trenk D, Sibbing D, Valgimigli M, Bonello L, On Behalf Of The Tailored Antiplatelet Treatment Study C. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2012;167:2140-2148.
8. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. American College of Cardiology F, American Heart Association Task Force on Practice G, Society for Cardiovascular A, Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122.
9. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention 2015;10:1024-1094.
10. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474-2483.
11. Mallouk N, Labruyere C, Reny JL, Chapelle C, Piot M, Fontana P, Gris JC, Delavenne X, Mismetti P, Laporte S. Prevalence of poor biological response to clopidogrel: A systematic review. Thromb Haemost 2012;107:494-506.
12. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD. Investigators A-D. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 2013;382:614-623.
13. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: Impact on thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132-1137.
14. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-762.
15. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schomig A, von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250-256.
16. Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 2010;104:571-581.
17. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Working Group on High On-Treatment Platelet R. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933.
18. Harrison P. Advances in the monitoring of anti-P2Y12 therapy. Platelets 2012;23:510-525.
19. Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K, European Platelet A. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors-is an algorithm the answer?. Thromb Haemost 2015;113:37-52.
20. Rohla M, Weiss TW, Wojta J, Niessner A, Huber K. Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. Eur Heart J Cardiovasc Pharmacother 2015;1:191-197.
21. Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthelemy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv 2013;6:158-165.
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
23. Lordkipanidze M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008;29:2877-2885.
24. Consuegra-Sanchez L, Lopez-Palop R, Cano P, Carrillo P, Pico F, Villegas M, Sanchis J, Kaski JC. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: Concordance between the multiplate and VerifyNow assays. J Thromb Haemost 2013;11:379-381.
25. Lemesle G, Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM. Poor agreement between light transmission aggregometry, VerifyNow P2Y(1)(2) and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials. Platelets 2014;25:499-505.
26. Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL. Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 2010;103:39-45.
27. Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 2011;24:529-534.
28. Soffer D, Moussa I, Harjai KJ, Boura JA, Dixon SR, Grines CL, O'neill WW, Roubin GS, Moses JW. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?.. Catheter Cardiovasc Interv 2003;59:21-25.
29. van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence. Platelets 2008;19:479-488.
30. Pendyala LK, Loh JP, Lhermusier T, Minha S, Magalhaes MA, Torguson R, Chen F, Satler LF, Pichard AD, Waksman R. Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?.. Am Heart J 2014;168:545-551.
31. Kakouros N, Kickler TS, Laws KM, Rade JJ. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. J Thromb Haemost 2013;11:1814-1822.
32. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158-167.
33. Penz SM, Bernlochner I, Toth O, Lorenz R, Calatzis A, Siess W. Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. Thromb J 2010;8:9.